A Phase 3 interventional study of Levodopa-carbidopa intestinal gel and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Parkinson's Disease, sponsored by AbbVie. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-05-30.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.
Among the 51 studies testing levodopa in Parkinson Disease, this one is the 36th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 12 in phase 3, and was the 33rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
Emory University · Sites in United States
Ages 45–75 · Healthy volunteers
Beth Israel Deaconess Medical Center · Sites in United States
By country, each count listing its studies:
Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 12 · Phase 4 17
First in 1998; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 50 interventional studies. Of the 45 that completed or were terminated, 18 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 51 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
44 studies in Parkinson Disease by AbbVie: 6 open now, 9 under way, none of them phase 3. Of 33 finished, 18 (55%) have results posted.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 10th registered.
AbbVie’s Parkinson Disease studies by the year they started, since 2006.
1 of the studies testing levodopa in Parkinson Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234995Emory UniversityCortical Electrophysiology of Response Inhibition in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing levodopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 44 in Parkinson Disease:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.
The study was composed of a screening period followed by 2 sequential on-treatment periods, as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment. The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour).
Drug: Levodopa-carbidopa intestinal gel · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: PEG tube · Device: J-tube
Drug pages: Levodopa · Carbidopa
Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Also known as: ABT-SLV187, LCIG
percutaneous endoscopic gastrostomy tube
jejunal tube
Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Parkinson's Disease Questionnaire (PDQ-39) Summary Index: Change From Baseline To The Final PEG-J Visit
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit
The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Time frame: Final PEG-J Visit (up to week 12)
Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit
The PGI-C is a 7-point response scale. The subjects were to rate their change in status from Screening Visit 1 using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Minimally improved," "Much improved," and "Very much improved" on the PGI-C were used to define responders.
Time frame: Final PEG-J Visit (up to week 12)
Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score: Change From Baseline To The Final PEG-J Visit
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Unified Parkinson's Disease Rating Scale (UPDRS) Part IIl Score: Change From Baseline To The Final PEG-J Visit
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Parkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit
The PDQ-39 is a self-administered questionnaire which comprises 39 items (each question answered on a 5-point scale) addressing 8 domains of health in Parkinson's disease patients: Mobility (e.g., fear of falling when walking) includes 10 questions; Emotional Well-being (e.g., feelings of isolation) includes 6 questions; Stigma (e.g., social embarrassment) includes 4 questions; Social Support includes 3 questions; Cognition includes 4 questions; Communication includes 3 questions; and Bodily Discomfort includes 3 questions. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score: Change From Baseline To The Final PEG-J Visit
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0 to176, with 176 representing the worst (total) disability, and 0 representing no disability.
Time frame: Baseline and Final PEG-J Visit (up to Week 12)
Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score: Change From Baseline To The Final PEG-J Visit
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0 to 16 and higher scores are associated with more disability.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score: Change From Baseline To The Final PEG-J Visit
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0 to 23 and higher scores are associated with more disability.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Average Daily Normalized "Off" Time Excluding Subjects Who Did Not Receive LCIG During the Entire PEG-J Period: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Average Daily Normalized "Off" Time Including All PD Diaries Regardless if They Were Completed After the Subject Had Used a Concomitant Anti-Parkinsonian Medication: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Average Daily Normalized "Off" Time at Baseline and Each Visit: Change From Baseline To The Final PEG-J Visit
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. n= the number of participants with available data at each time point.
Time frame: Baseline (end of screening period) and Weeks 2, 4, 6, 8, 10, and 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent AEs (TEAEs) are defined as any event that began or worsened in severity after N-J placement. The investigator assessed the relationship of each event to the use of study drug as Reasonable Possibility or No Reasonable Possibility. For more details on adverse events please see the AE section below.
Time frame: From N-J placement to the end of study or early termination of treatment, including the removal of PEG-J (up to 17 weeks), plus 30 days.
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), body temperature (Temp), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively.
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
Terms abbreviated in the table include females (f), males (m), and femtoliters (fL).
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Number of Participants With Potentially Clinically Significant Values for 12-lead Electrocardiogram (ECG)
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), QT interval corrected for heart rate using Fridericia's formula (QTcF), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively. n = the number of participants with available data at each time point.
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Neurological Examination
Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for neurological examination findings was not performed per protocol.
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Physical Examination
Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for physical examination findings was not performed per protocol.
Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
| Milestone | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Started | 31 |
| Completed | 28 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 7.37 ± 2.263 |
| Last PEG-J visit | 2.72 ± 2.320 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 7.52 ± 2.505 |
| Last PEG-J visit | 13.10 ± 2.453 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 35.5 ± 13.75 |
| Last PEG-J visit | 23.5 ± 13.59 |
The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit | 1.9 ± 0.77 |
The PGI-C is a 7-point response scale. The subjects were to rate their change in status from Screening Visit 1 using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Minimally improved," "Much improved," and "Very much improved" on the PGI-C were used to define responders.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit | 2.0 ± 0.94 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 9.4 ± 6.63 |
| Last PEG-J visit | 7.6 ± 6.93 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 16.5 ± 9.70 |
| Final PEG-J visit | 14.3 ± 11.30 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 1.12 ± 2.311 |
| Last PEG-J visit | 0.12 ± 0.394 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items (each question answered on a 5-point scale) addressing 8 domains of health in Parkinson's disease patients: Mobility (e.g., fear of falling when walking) includes 10 questions; Emotional Well-being (e.g., feelings of isolation) includes 6 questions; Stigma (e.g., social embarrassment) includes 4 questions; Social Support includes 3 questions; Cognition includes 4 questions; Communication includes 3 questions; and Bodily Discomfort includes 3 questions. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Mobility Domain-Baseline | 55.7 ± 19.46 |
| Mobility Domain-Last PEG-J visit | 36.5 ± 22.49 |
| Emotional Well-Being Domain-Baseline | 30.8 ± 19.13 |
| Emotional Well-Being Domain-Last PEG-J visit | 24.3 ± 18.02 |
| Stigma Domain-Baseline | 20.6 ± 22.21 |
| Stigma Domain-Last PEG-J visit | 13.1 ± 20.78 |
| Social Support Domain-Baseline | 16.1 ± 18.69 |
| Social Support Domain-Last PEG-J visit | 14.6 ± 21.35 |
| Cognition Domain-Baseline | 28.5 ± 19.26 |
| Cognition Domain-Last PEG-J visit | 14.6 ± 13.16 |
| Communication Domain-Baseline | 13.3 ± 14.62 |
| Communication Domain-Last PEG-J visit | 14.4 ± 16.94 |
| Bodily Discomfort Domain-Baseline | 35.0 ± 21.60 |
| Bodily Discomfort Domain-Last PEG-J visit | 17.2 ± 14.83 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0 to176, with 176 representing the worst (total) disability, and 0 representing no disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 27.7 ± 15.53 |
| Last PEG-J visit | 22.9 ± 17.53 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0 to 16 and higher scores are associated with more disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 1.8 ± 2.02 |
| Last PEG-J visit | 0.9 ± 0.91 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0 to 23 and higher scores are associated with more disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 8.7 ± 3.15 |
| Last PEG-J visit | 5.5 ± 3.08 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 7.32 ± 2.290 |
| Last PEG-J visit | 2.67 ± 2.341 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline | 7.37 ± 2.263 |
| Last PEG-J visit | 2.78 ± 2.382 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. n= the number of participants with available data at each time point.
| hours | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Baseline (n=29) | 7.37 ± 2.263 |
| Week 2 (n=29) | 3.17 ± 2.365 |
| Week 4 (n=29) | 3.68 ± 3.077 |
| Week 6 (n=29) | 2.61 ± 2.318 |
| Week 8 (n=27) | 2.77 ± 2.324 |
| Week 10 (n=27) | 2.47 ± 2.210 |
| Week 12 (n=27) | 2.45 ± 2.094 |
An adverse event (AE) is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent AEs (TEAEs) are defined as any event that began or worsened in severity after N-J placement. The investigator assessed the relationship of each event to the use of study drug as Reasonable Possibility or No Reasonable Possibility. For more details on adverse events please see the AE section below.
| participants | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Any TEAE | 31 |
| Any TEAE at least possibly related to LCIG | 0 |
| Any TEAE at least possibly related to LCIG System | 30 |
| Any severe TEAE | 2 |
| Any SAE | 4 |
| Any TEAE Leading to Discontinuation of Study | 1 |
| Death | 1 |
| Death related to AE | 1 |
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), body temperature (Temp), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively.
| participants | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| SuSBP <=90 and >30 mm Hg ↓ from BL | 3 |
| SuSBP >=180 and >40 mm Hg ↑ from BL | 1 |
| StSBP <=90 and >30 mm Hg ↓ from BL | 3 |
| StSBP >=180 and >40 mm Hg ↑ from BL | 1 |
| OSBP: ↓ >=30 mm Hg Supine to Standing | 8 |
| SuDBP <=50 and >30 mm Hg ↓ from BL | 1 |
| SuDBP >=105 and >30 mm Hg ↑ from BL | 1 |
| StDBP <=50 and >30 mm Hg ↓ from BL | 3 |
| StDBP >=105 and >30 mm Hg ↑ from BL | 3 |
| ODBP: ↓ >=20 mm Hg Supine to Standing | 11 |
| SuP <=50 and >30 bpm ↓ from BL | 0 |
| SuP >=120 and >30 bpm ↑ from BL | 0 |
| StP <=50 and >30 bpm ↓ from BL | 0 |
| StP >=120 and >30 bpm ↑ from BL | 0 |
| Weight <=7% ↓ from BL | 8 |
| Weight >=7% ↑ from BL | 2 |
Terms abbreviated in the table include females (f), males (m), and femtoliters (fL).
| participants | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Haemoglobin <90 g/L (f); <100 g/L (m) | 1 |
| Haematocrit <30% (f); <34% (m) | 2 |
| Red Blood Cells <2.0 10^12/L (f); <2.5 10^12/L (m) | 0 |
| Platelet Count <95 10^9/L | 1 |
| Platelet Count >700 10^9/L | 0 |
| White Blood Cells <2.8 10^9/L | 0 |
| White Blood Cells >16.0 10^9/L | 1 |
| Lymphocytes >80% | 0 |
| Monocytes >30% | 0 |
| Eosinophils >10% | 1 |
| Mean Corpuscular Volume <60 fL | 0 |
| Mean Corpuscular Volume >120 fL | 0 |
Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).
| participants | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Alanine Aminotransferase >3xULN | 1 |
| Aspartate Aminotransferase >3xULN | 1 |
| Gamma-glutamyl Transferase >3x ULN | 0 |
| Alkaline Phosphatase >400 U/L | 0 |
| Total Bilirubin >2xULN | 0 |
| Creatine Phosphokinase >3x ULN | 0 |
| Creatinine >177 µmol/L | 0 |
| Blood Urea Nitrogen >10.8 mmol/L | 2 |
| Uric Acid>500µmol/L(f);>590µmol/L(m) | 0 |
| Calcium <1.75 mmol/L | 0 |
| Calcium >3.0 mmol/L | 0 |
| Sodium <126 mmol/L | 0 |
| Sodium >156 mmol/L | 0 |
| Potassium <3.0 mmol/L | 1 |
| Potassium >6.0 mmol/L | 0 |
| Non-fasting Glucose <2.78 mmol/L | 1 |
| Non-fasting Glucose >16.0 mmol/L | 1 |
| Albumin <25 g/L | 1 |
| Albumin >70 g/L | 0 |
| Total Protein <45 g/L | 0 |
| Cholesterol >12.9 mmol/L | 0 |
| Triglycerides >5.6 mmol/L | 0 |
| Lactate dehydrogenase >3x ULN | 0 |
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), QT interval corrected for heart rate using Fridericia's formula (QTcF), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively. n = the number of participants with available data at each time point.
| participants | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| HR <=50 and >30 bpm ↓ from BL (n=31) | 0 |
| HR >=120 and >30 bpm ↑ from BL (n=31) | 0 |
| PR Interval <120 msec (n=30) | 0 |
| PR Interval >220 msec (n=30) | 1 |
| QTcB Interval >480 msec (n=31) | 1 |
| QTcB Interval >60 msec ↑ from BL (n=31) | 1 |
| QTcF Interval >480 msec (n=31) | 0 |
| QTcF Interval >60 msec ↑ from BL (n=31) | 1 |
Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for neurological examination findings was not performed per protocol.
Results for this outcome have not been posted.
Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for physical examination findings was not performed per protocol.
Results for this outcome have not been posted.
Collected over From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J (up to 17 weeks), plus 30 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levodopa-Carbidopa Intestinal Gel (LCIG) | — | 4/31 (12.9%) | 31/31 (100%) |
| Event | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders | 2/31 |
| DISSEMINATED INTRAVASCULAR COAGULATIONBlood and lymphatic system disorders | 1/31 |
| ABDOMINAL PAINGastrointestinal disorders | 1/31 |
| CONSTIPATIONGastrointestinal disorders | 1/31 |
| GASTROINTESTINAL PERFORATIONGastrointestinal disorders | 1/31 |
| MELAENAGastrointestinal disorders | 1/31 |
| DEVICE DISLOCATIONGeneral disorders | 1/31 |
| DEVICE KINKGeneral disorders | 1/31 |
| SEPSISInfections and infestations | 1/31 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 1/31 |
| Event | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| INCISION SITE PAINInjury, poisoning and procedural complications | 13/31 |
| EXCESSIVE GRANULATION TISSUESkin and subcutaneous tissue disorders | 10/31 |
| CONSTIPATIONGastrointestinal disorders | 6/31 |
| DIARRHOEAGastrointestinal disorders | 6/31 |
| NASOPHARYNGITISInfections and infestations | 6/31 |
| FALLInjury, poisoning and procedural complications | 6/31 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 5/31 |
| BLOOD HOMOCYSTEINE INCREASEDInvestigations | 5/31 |
| DYSKINESIANervous system disorders | 5/31 |
| INCISION SITE ERYTHEMAInjury, poisoning and procedural complications | 4/31 |
Safety Analysis Set: All subjects who had undergone the N-J placement procedure.
| Age, Continuous(years) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Mean | 61.6 ± 10.50 |
| Sex: Female, Male(Participants) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Female | 19 |
| Male | 12 |
| Duration of Parkinson's Disease Since Initial Diagnosis(years) | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Mean | 12.4 ± 5.08 |
No study locations are listed for this record.
The record gives a start of Oct 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa